Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 3/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.33 |
| ▸ | CDK1 | P06493 | 3/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.33 |
| ▸ | GSK3A | P49840 | 3/20 | 0.33 |
| ▸ | GSK3B | P49841 | 3/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.33 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL311312 | 0.79 | KDM4E (0.41) | ADRA1AKDM4EKMT2AMEN1ALDH1A1 | |
| SCHEMBL22733525 | 0.77 | ADRA2A (0.41) | ADRA2AADRA2CADRA1AADRA2BADRA1D | |
| SCHEMBL7325665 | 0.77 | ALDH1A1 (0.44) | ADRA2AADRA2CADRA1AADRA2BADRA1D | |
| SCHEMBL10752889 | 0.74 | MAPT (0.52) | KDM4EKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL5942607 | 0.73 | TGFBR1 (0.39) | ADRA2AADRA2CADRA1AADRA2BADRA1D | |
| SCHEMBL1926253 | 0.69 | RXFP1 (0.38) | KDM4EKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL87693 | 0.68 | MAPT (0.50) | ADRA2AADRA2CADRA1AADRA2BADRA1D | |
| SCHEMBL30335572 | 0.68 | MAPT (0.50) | ADRA2AADRA2CADRA1AADRA2BADRA1D | |
| SCHEMBL29463681 | 0.68 | MAPT (0.50) | ADRA2AADRA2CADRA1AADRA2BADRA1D | |
| SCHEMBL9405141 | 0.68 | KDM4E (0.43) | KDM4EKMT2AMEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3240789-B1 | NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER | UNIV MONTPELLIER (FR) | 2020-07-29 | — | — | EP | disclosed |
| US-10689384-B2 | Imidazo[1,2-a]quinoxalines and derivatives thereof for the treatment of cancer | UNIVERSITE DE MONTPELLIER (FR) | 2020-06-23 | — | — | US | disclosed |
| EP-2205602-B1 | IMIDAZO[1,2-A]QUINOXALINES AND DERIVATIVES THEREOF FOR TREATING CANCERS | UNIV MONTPELLIER (FR) | 2018-09-26 | — | — | EP | disclosed |
| US-20180016278-A1 | Imidazo[1,2-a]quinoxalines and Derivatives Thereof for the Treatment of Cancer | AXLR, SATT DU LANGUEDOC ROUSSILLON (FR) | 2018-01-18 | — | — | US | disclosed |
| EP-3240789-A1 | NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER | Université de Montpellier (FR) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016107895-A1 | NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER | UNIVERSITE DE MONTPELLIER (FR) | 2016-07-07 | — | — | WO | disclosed |
| US-8378098-B2 | Imidazol[1,2-α]quinoxalines and derivatives for the treatment of cancers | UNIVERSITE DE MONTPELLIER I (FR) | 2013-02-19 | — | — | US | disclosed |
| US-20100249142-A1 | IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS | UNIVERSITE DE MONTPELLIER I | 2010-09-30 | — | — | US | disclosed |
| EP-2205602-A1 | IMIDAZOÝL,2- ¨QUINOXALINES AND DERIVATIVES THEREOF FOR TREATING CANCERS | Université de Montpellier I (FR) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009043934-A1 | IMIDAZO[L,2-α]QUINOXALINES AND DERIVATIVES THEREOF FOR TREATING CANCERS | UNIVERSITE DE MONTPELLIER I (FR) | 2009-04-09 | — | — | WO | disclosed |
| EP-0743945-B1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK AS (DK) | 2002-03-06 | — | — | EP | disclosed |
| US-5741785-A | IMIDAZOLO(1,2-A)QUINOXALINONE COMPOUNDS; ANTIISCHEMIC AGENTS; NERVOUS SYSTEM DISORDERS | NOVO NORDISK A/S (DK) | 1998-04-21 | — | — | US | disclosed |
| EP-0743945-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1996-11-27 | — | — | EP | disclosed |
| US-5473073-A | Useful in diagnosis or treatment of anxiety, sleep and seizure disorders, overdose with bezodiazepine drug and memory enhancement | NEUROGEN CORPORATION (US) | 1995-12-05 | — | — | US | disclosed |
| US-5473073-A | Useful in diagnosis or treatment of anxiety, sleep and seizure disorders, overdose with bezodiazepine drug and memory enhancement | NEUROGEN CORPORATION (US) | 1995-12-05 | — | — | US | disclosed |
| WO-1995021842-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1995-08-17 | — | — | WO | disclosed |
| WO-1993004066-A1 | CERTAIN IMIDAZOQUINOXALINOLS; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1993-03-04 | — | — | WO | disclosed |
| US-5182386-A | G-Aminobutyric Acid | NEUROGEN CORPORATION (US) | 1993-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689384-B2 | Imidazo[1,2-a]quinoxalines and derivatives thereof for the treatment of cancer | NQO1, NQO2, ABL1 | ADRA2A 810/4885ADRA2C 1083/4885ADRA1A 775/4885 |
| US-20100249142-A1 | IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS | IDH3A, NRAS, KRAS | ADRA2A 813/4885ADRA2C 689/4885ADRA1A 899/4885 |
| US-20180016278-A1 | Imidazo[1,2-a]quinoxalines and Derivatives Thereof for the Treatment of Cancer | NQO1, NQO2, ABL1 | ADRA2A 810/4885ADRA2C 1083/4885ADRA1A 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.